LPM3770277, a Potent Novel CDK4/6 Degrader, Exerts Antitumor Effect Against Triple-Negative Breast Cancer
Source : https://www.frontiersin.org/articles/10.3389/fphar.2022.853993/full
Triple negative breast cancer (TNBC) is a subtype of breast cancer with significant malignancy and poor prognosis but effective treatments are limited. Given the critical role of CDK4/6 in cell...
Conclusion: In conclusion, this study for the first time developed and characterized a CDK4/6 degrader against TNBC using hydrophobic tags, which strongly suggests the viability of hydrophobic tags as a strategy to develop potential treatments against TNBC.
Trends in female breast cancer incidence, mortality, and survival in Austria, with focus on age, stage, and birth cohorts (1983-2017) - Scientific Reports
Source : https://www.nature.com/articles/s41598-022-10560-x
Breast cancer (BC) is the most commonly diagnosed malignant disease and the leading cause of cancer death in women in Austria. We investigated overall and subgroup-specific female breast cancer rates...
Relevance: Breast cancer (BC) is the most commonly diagnosed malignant disease and the leading cause of cancer death in women in Austria. We investigated overall and subgroup-specific female breast cancer rates to provide a comprehensive analysis of trends over several decades. Incidence, mortality, and survival, as well as age-, stage-, and...
CDK4/6 inhibitors: a brief overview and prospective research directions
Source : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9040853/
The discovery of cyclin-dependent kinases (CDK) and their mechanism in regulating the cell cycle process was considered a game-changer in cancer therapy. Cell cycle arrest and apoptosis were both triggered...
Relevance: Overall, our prime focus is to discuss novel CDK4/6 inhibitors with diverse chemical classes and their correlation with computational studies.
For those awaiting the published results of DESTINY-03 (T-DXd vs T-DM1 in the second line). I did not see this posted recently, but these data are impactful and will likely result in the expanded FDA approval of T-DXd to include second line. The question that remains is where T-DXd and the HER2CLIMB (Trastuzumab capecitabine tucatinib, which...
Cost-Savings Analysis of an Individualized Exercise Oncology Program in Early-Stage Breast Cancer Survivors: A Randomized Clinical Control Trial - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35363502/
Purpose: In an attempt to promote the integration of exercise oncology as a standard part of clinical practice, economic evaluations are warranted. Thus, the purpose of this study was to...
Conclusion: A supervised, individualized 12-week exercise intervention led to significant improvements in fitness parameters and ECOG scores, as well as a decrease in unplanned health care utilization among early-stage breast cancer survivor
-
Sarah Mougalian, Yale Cancer Center4yrWe are going to start to see more and more lifestyle-based data on energy balance coming out in the breast cancer literature, as we look for non-pharmacologic ways to improve Show More
-
Albert Dekker4yrand after 12? any longerterm f/u